BPARBiopsy-Proven Acute Rejection
BPARBlack-Pigmented Anaerobic Rods (dentistry)
Copyright 1988-2018 AcronymFinder.com, All rights reserved.
References in periodicals archive ?
ECDs as a result of DCD and donation after brain death are defined separately for kidneys according to the United Network for Organ Sharing definition.[4] The recipients of ECD kidneys are often excluded from transplant trials due to the higher rate of delayed graft function (DGF), more biopsy-proven acute rejection (BPAR), decreased long-term graft function, calcineurin inhibitor (CNI)-induced nephrotoxicity, increased incidence of infection, cardiovascular risk, and malignancies.[5],[6] For this reason, the ideal immunosuppressive regimen for this population has not yet been defined.
End points studied were as follows: (1) patient survival at 1st year, (2) graft survival at 1st year, (3) DGF, (4) 1-year serum creatinine and estimated glomerular filtration rate (eGFR), and (5) the BPAR rate in the 1st year.
Rates of BPAR and steroid-resistant BPAR were also significantly lower under rATG [50] (Table 2).
Nonrandomized trials have also shown lower rates of DGF and BPAR compared to IL-2RA induction when rATG is started intraoperatively in patients at high immunological risk [68,69], with mixed evidence for a benefit for DGF when rATG is initiated after surgery in mixed-risk populations [11, 70] or in low- or moderate-risk populations even if the first dose of rATG is given before reperfusion [71].
The composite endpoint was considered when BPAR was absent and eGFR [greater than or equal to] 60 mL/min/1.73[m.sub.2] was present.
Abbreviations ADV: Adenovirus ANA: Antinuclear antibody BPAR: Biopsy-proven acute rejection DSA: Donor-specific HLA-antibody HCMV: Human cytomegalovirus DMSO: Dimethylsulfoxide DSMB: Data safety monitoring board EBV: Epstein-Barr virus INR: International normalized ratio IS: Immunosuppression ICU: Intensive care unit ISCT: International Society of Cellular Therapy LDLT: Living-donor liver transplantation LKMA: Anti-liver-kidney microsomal antibody LT: Liver transplantation MDSC: Myeloid-derived immunosuppressive cell MSC: Mesenchymal stem (stromal) cell pLT: Pediatric liver transplantation RI: Resistance index RT-PCR: Reverse transcription polymerase chain reaction TA Vmax: Time-averaged maximum velocity SAE: Severe adverse event SMA: Anti-smooth muscle antibody.
Earlier, the Finance Minister distributed BPAR Awards and Certificates of Merit among the representatives of selected firms and companies.
BPAR occurred in 37 of the 185 patients, 4 of whom carried CYP3A4 intron 6 variant T, but no significant differences in BPAR incidence were observed between carriers of the T variant and CC patients [[chi square] (1) = 1.42; P = 0.23].
In another retrospective study assessing conversion (medium quality), BPAR among patients converted at various times was 3.4% [67], while a medium quality review of a prospectively maintained database revealed an acute cellular rejection rate of 17.2% for those treated de novo with sirolimus versus 2.8% for those converted at various timepoints to sirolimus in response to rising serum creatinine concentrations [69].
The primary efficacy endpoint was a composite of death, graft failure, biopsy-proven acute rejection (BPAR) via a local pathology reading or loss to follow-up within 12 months of randomisation.
CTI says the primary endpoint of the trial is defined as non-inferiority in biopsy proven acute rejection (BPAR) episodes in patients receiving ISA247 for six months compared to the tacrolimus control.